Association of p53 gene mutation with decreased chemosensitivity in human malignant gliomas

International Journal of Cancer

Volumn 69, Issue 3, 1996, Pages 236-240

  Iwadate, Yasuo ^a   Fujimoto, Shuichi ^b   Taoawa, Masatoshi ^a   Namba, Hiroki ^b   Sueyoshi, Kanji ^b   Hirose, Masayoshi ^b   Sakiyama, Shigeru ^b  

^a CHIBA UNIVERSITY   (Japan)

^b CHIBA CANCER CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROPEROXYCYCLOPHOSPHAMIDE; 4 HYDROPEROXYIFOSFAMIDE; ACLARUBICIN; ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBOPLATIN; CARBOQUONE; CHLOMOMYCIN; CISPLATIN; CYTARABINE; DACTINOMYCIN; DAUNORUBICIN; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; MELPHALAN; MERCAPTOPURINE RIBOSIDE; METHOTREXATE; MITOMYCIN C; MITOXANTRONE; NIMUSTINE; PEPLEOMYCIN; PIRARUBICIN; PROTEIN P53; RANIMUSTINE; UNCLASSIFIED DRUG; VINBLASTINE; VINCRISTINE; VINDESINE; ZINOSTATIN;

ADULT; AGED; APOPTOSIS; ARTICLE; ASTROCYTOMA; CHEMOSENSITIVITY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FETAL CALF SERUM; GENE MUTATION; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; APOPTOSIS; BASE SEQUENCE; BRAIN NEOPLASMS; DNA, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; FLOW CYTOMETRY; GENES, P53; GLIOMA; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL;

EID: 0030036839     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19960621)69:3<236::AID-IJC14>3.0.CO;2-5     Document Type: Article

References (30)

1. BIARD, D.S.F., MARTIN, M., LE RHUN, Y., DUTHU, A., LEFAIX, J.L., MAY, E. and MAY, P., Concomitant p53 gene mutation and increased radiosensitivity in rat lung embryo epithelial cells during neoplastic development. Cancer Res., 54, 3361-3364 (1994).
2. BRACHMAN, D.G., BECKETT, M., GRAVES, D., HARAF, D., VOKES, E. and WEIcHSELBAUM, R.R., p53 mutation does not correlate with radiosensitivity in 24 head-and-neck cancer cell lines. Cancer Res., 53, 3667-3669 (1993).
3. CARBONE, D.P. and MINNA, J.D., In vivo gene therapy of human lung cancer using wild-type p53 delivered by retrovirus. J. nat. Cancer Inst., 86, 1437-1438 (1994).
4. CLARKE, A.R., PURDIE, C.A., HARRISON, D.J., MORRIS, R.G., BIRD, C.C., HOOPER, M.L. and WYLLIE, A.H., Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature (Lond.), 362, 849-852 (1993).
5. CLAYMAN, G.L., EL-NAGGAR, A.K., ROTH, J.A., ZHANG, W-W., GOEPFERT, H., TAYLOR, D.L. and LIU, T.-J., In vivo molecular therapy with p53 adenovirus for microscopic residual head-and-neck squamous carcinoma. Cancer Res., 55, 1-6 (1995).
6. FAN, S., EL-DEIRY, W.S., BAE, I., FREEMAN, J., JONDEE, D., BHATIA, K., FORNACE, A.J. JR., MAGRATH, I., KOHN, K.W. and O'CONNOR, P.M., p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res., 54, 5824-5830 (1994).
7. FUJIWARA, T., GRIMM, E.A., MUKHOPADHYAY, T., ZHANG, W-W., OWEN-SCHAUB, L.B. and ROTH, J.A., Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res., 54, 2287-2291 (1994).
8. HAYASHI, Y., YAMASHITA, J. and YAMAGUCHI, K., Timing and role of p53 gene mutation in the recurrence of glioma. Biochem. biophys. Res. Comm., 180, 1145-1150 (1991).
9. IWADATE, Y., NAMBA, H., SUEYOSHI, K. and FUJIMOTO, S., Assessment of antitumor activity with flow cytometry using a DNA binding dye. Proc. XVI Int. Cancer Congress, Vol. 16, pp. 525-529 Monduzzi Editore, Bologna (1994).
10. JUNG, M., NOTARIO, V. and DRITSCHILO, A., Mutation in the p53 gene in radiation-sensitive and -resistant human squamous carcinoma cells. Cancer Res., 52, 6390-6393 (1992).
11. KASTAN, M.B., ONEYKWERE, O., SIDRANSKY, D., VOGELSTEIN, B. and CRAIG, R.W., Participation of p53 protein in the cellular response to DNA damage. Cancer Res., 51, 6304-6311 (1991).
12. KUERBITZ, S.J., PLUNKETT, B.S., WALSH, W.W. and KASTAN, M.B., Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. nat. Acad. Sci. (Wash.), 89, 7491-7495 (1992).
13. LANE, D.P., p53, guardian of the genome. Nature (Lond), 358, 15-16 (1992).
14. LANG, F.F., MILLER, D.C., KOSLOW, M. and NEWCOMB, E.W., Pathways leading to glioblastoma multiforme: a molecular analysis of genetic alterations in 65 astrocytic tumors. J. Neurosurg., 81, 427-436 (1994).
15. LEE, J.M. and BERNSTEIN, A., p53 mutations increase resistance to ionizing radiation. Proc. nat. Acad. Sci. (Wash.), 90, 5742-5746 (1993).
16. LIU, T-J., ZHANG, W-W., TAYLOR, D.L., ROTH, J.A., GOEPFERT, H. and CLAYMAN, G.L., Growth suppression of human head and neck cancer cells by the introduction of a wild-type p53 gene via a recombinant adenovirus. Cancer Res., 54, 3662-3667 (1994).
17. LOWE, S.W., RULEY, H.E., JACKS, T. and HOUSMAN, D.E., p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell, 74, 957-967 (1993).
18. MCILWRATH, A.J., VASEY, P.A., Ross, G.M. and BROWN, R., Cell cycle arrests and radiosensitivity of human tumor cell lines: dependence on wild-type p53 for radiosensitivity. Cancer Res., 54, 3718-3722 (1994).
19. MURAKAMI, Y., HAYASHI, K. and SEKIYA, T., Detection of aberrations of the p53 alleles and the gene transcript in human tumor cell lines by single-strand conformation polymorphism analysis. Cancer Res., 51, 3356-3361 (1991).
20. NICOLETTI, I., MlGLIORATI, G., PAGLIACCI, M.C., GRIONANI, F. and RICCARDI, C., A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J immunol. Meth., 139, 271-279 (1991).
21. O'CONNOR, P.M., JACKMAN, J., JONDLE, D., BHATIA, K., MAGRATH, I. and KOHN, K.W., Role of the p53 tumor-suppressor gene in cell cycle arrest and radiosensitivity of Burkitt's lymphoma cell lines. Cancer Res., 53, 4776-4780 (1993).
22. PETTY, R.D., CREE, I.A., SUTHERLAND, L.A., HUNTER, E.M., LANE, D.P., PREECE, P.E. and ANDREOTTI, P.E., Expression of the p53 tumor-suppressor gene product is a determinant of chemosensitivity. Biochem. biophs. Res. Comm., 199, 264-270 (1994).
23. SENTMAN, C.L., SHUTTER, J.R., HOCKENBERY, D., KANAGAWA, O. and KORSMEYER, S.J., bc1-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes. Cell, 67, 879-888 (1991).
24. SIDRANSKY, D., MIKKELSEN, T., SCHWECHHEIMER, K., ROSENBLUM, M.L., CAVANEE, W. and VOGELSTEIN, B., Clonal expansion of p53 mutant cells is associated with brain-tumor progression. Nature (Lond.), 355, 846-847 (1992).
25. 1 checkpoint does not decrease cell survival following DNA damage. Cancer Res., 53, 4164-4168 (1993).
26. TAKAHASHI, T., CARBONE, D., TAKAHASHI, T., NAU, M.M., HIDA, T., LINNOILA, I., UEDA, R. and MINNA, J.D., Wild-type but not mutant p53 suppresses the growth of human lung cancer cells bearing multiple genetic lesions. Cancer Res., 52, 2340-2343 (1992).
27. WALKER, M.D., GREEN, S.B., BYAR, D.P., ALEXANDER, E., JR., BATZDORF, U., BROOKS, W.H., HUNT, W.E., MACCARTY, C.S., MAHALEY, M.S., JR., MEALEY, J., JR., OWENS, G., RANSOHOFF, J., II, ROBERTSON, J.T., SHAPIRO, W.R., SMITH, K.R., JR., WILSON, C.B. 2nd STRIKE, T.A., Randomized comparisons of radiotherapy and nitrosourea for the treatment of malignant glioma after surgery. New Engl. J. Med., 303, 1323-1329 (1980).
28. WANG, Y., RAMOVIST, T., SZEKELY, L., AXELSON, H., KLEIN, G. and WIMAN, K.D., Reconstitution of wild-type p53 expression triggers apoptosis in a p55-negative v-myc retrovirus-induced T-cell lymphoma line. Cell Growth Diff., 4, 467-473 (1993).
29. WILLS, K.N., MANEVAL, D.C., MENZEL, P., HARRIS, M.P., SUTJIPTO, S., VAILLANCOURT, M-T., HUANG, W-M., JOHNSON, D.E., ANDERSON, S.C., WEN, S.F., BOOKSTEIN, R., SHEPARD, H.M. and GREGORY, R.J., Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancer. Hum. Gene Ther., 5, 1079-1088 (1994).
30. WU, X., BAYLE, J.H., OLSON, D. and LEVINE, A.J., The p53-mdm-2 autoregulatory feedback loop. Genes Devel., 7, 1126-1132 (1993).